netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 21 of 21


Details
UPD sitematrix Changed from 0 to
20/11/2023 12:39:05
(DavidS )
UPD FurtherInformation Changed from
  • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE



&nbs

20/11/2023 12:39:05
(DavidS )
UPD Neratinib (Nerlynx®) updated
20/11/2023 12:39:05
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 15:18:58
(LoweryM )
UPD FurtherInformation Changed from

 

    • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
27/07/2022 15:18:58
(LoweryM )
UPD Neratinib (Nerlynx®) formatting
27/07/2022 15:18:58
(LoweryM )
UPD sitematrix Changed from 0 to
27/07/2022 14:51:15
(DavidS )
UPD BlueTeq Changed from N to Y
27/07/2022 14:51:15
(DavidS )
UPD FurtherInformation Changed from

  • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE


 

to

27/07/2022 14:51:15
(DavidS )
UPD Neratinib (Nerlynx®) updated
27/07/2022 14:51:15
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 12:05:15
(DavidS )
UPD FurtherInformation Changed from

 

    • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
26/04/2022 12:05:15
(DavidS )
UPD Neratinib (Nerlynx®) updated
26/04/2022 12:05:15
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 11:34:56
(DavidS )
UPD isCyto Changed from 0 to 1
26/04/2022 11:34:56
(DavidS )
UPD FurtherInformation Changed from

  • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE

to

 
26/04/2022 11:34:56
(DavidS )
UPD Neratinib (Nerlynx®) updated
26/04/2022 11:34:56
(DavidS )
LDL Link Added : NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab : https://www.nice.org.uk/guidance/ta612
13/02/2020 14:52:41
(DavidS )
UPD Published from Draft Mode
27/12/2019 12:39:12
(DavidS )
UPD Neratinib (Nerlynx®) trade name added
21/11/2019 16:04:26
(LoweryM )
ADD Neratinib add
29/10/2019 15:27:02
(DavidS )

 

 
netFormulary